RT Journal Article
SR Electronic
T1 Pulmonary Embolism in Patients with COVID-19: A Systematic review and Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.09.20209965
DO 10.1101/2020.10.09.20209965
A1 Hamam, Omar
A1 Goda, Ahmed
A1 Awad, Radwa
A1 Ussama, Amr
A1 Eldalal, Moustafa
A1 Fayez, Ahmed
A1 Baral, Smarika
A1 Elyamany, Karim
A1 Bhandari, Renu
A1 Egbe, Alexander
A1 Sharina, Iraida
YR 2020
UL http://medrxiv.org/content/early/2020/10/09/2020.10.09.20209965.abstract
AB Background There is an increasing evidence that COVID-19 could be complicated by coagulopathy which may lead to death; especially in severe cases. Hence, this study aimed to build concrete evidence regarding the incidence and mortality of pulmonary embolism (PE) in patients with COVID-19.Methods We performed a systematic search for trusted databases/search engines including PubMed, Scopus, Cochrane library and web of science. After screening, the relevant data were extracted and the incidences and mortality rates from the different included studies were pooled for meta-analysis.Results Twenty studies were finally included in our study consisting of 1896 patients. The results of the meta-analysis for the all included studies showed that the incidence of PE in patients with COVID-19 was 17.6% with the 95% confidence interval (CI) of 12.7 to 22.5%. There was significant heterogeneity (I2□=□91.17%). Additionally, the results of meta-analysis including 8 studies showed that the mortality in patients with both PE and COVID-19 was 43.1% with the 95% confidence interval (CI) of 19 to 67.1%. There was significant heterogeneity (I2□=□86.96%).Conclusion PE was highly frequent in patients with COVID-19. The mortality in patients with both COVID-19 and PE was remarkable representing almost half of the patients. Appropriate prophylaxis and management are vital for better outcomesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not needed for this designAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable upon request from the corresponding author